Development of the ISI-RSV for patients presenting with RSV infections (N = 237)
| . | . | No. (%) . | . | . | . | |
|---|---|---|---|---|---|---|
| Criteria . | . | Patients 237, n (%) . | Progression to LRTI 37, n (%) . | AHR* (95% CI) . | Weighing criteria . | Assigned weights (score) . |
| 1 | ANC <500/μL | 11 (5) | 7 (64) | 4.1 (1.4-11.6) | >2.5 | 3 |
| 2 | ALC <200/μL | 35 (15) | 11 (31) | 2.6 (1.02-6.4) | >2.5 | 3 |
| 3 | Age ≥40 y | 154 (65) | 28 (18) | 2.5 (1.1-5.6) | 2.0-2.5 | 2 |
| 4 | Myeloablative conditioning regimen | 98 (41) | 17 (17) | 1.2 (0.6-2.3) | <2.0 | 1 |
| 5 | GVHD (acute or chronic) | 149 (63) | 19 (13) | 1.0 (0.5-2.2) | <2.0 | 1 |
| 6 | Corticosteroids† | 117 (49) | 17 (15) | 0.89 (0.4-1.8) | <2.0 | 1 |
| 7 | Recent† or pre-engraftment allo-HSCT | 21 (9) | 5 (24) | 0.68 (0.2-2.3) | <2.0 | 1 |
| Maximum possible overall score‡ | 12 | |||||
| Low risk: 0-2 score, moderate risk 3-6 score, high risk 7-12 score | ||||||
| . | . | No. (%) . | . | . | . | |
|---|---|---|---|---|---|---|
| Criteria . | . | Patients 237, n (%) . | Progression to LRTI 37, n (%) . | AHR* (95% CI) . | Weighing criteria . | Assigned weights (score) . |
| 1 | ANC <500/μL | 11 (5) | 7 (64) | 4.1 (1.4-11.6) | >2.5 | 3 |
| 2 | ALC <200/μL | 35 (15) | 11 (31) | 2.6 (1.02-6.4) | >2.5 | 3 |
| 3 | Age ≥40 y | 154 (65) | 28 (18) | 2.5 (1.1-5.6) | 2.0-2.5 | 2 |
| 4 | Myeloablative conditioning regimen | 98 (41) | 17 (17) | 1.2 (0.6-2.3) | <2.0 | 1 |
| 5 | GVHD (acute or chronic) | 149 (63) | 19 (13) | 1.0 (0.5-2.2) | <2.0 | 1 |
| 6 | Corticosteroids† | 117 (49) | 17 (15) | 0.89 (0.4-1.8) | <2.0 | 1 |
| 7 | Recent† or pre-engraftment allo-HSCT | 21 (9) | 5 (24) | 0.68 (0.2-2.3) | <2.0 | 1 |
| Maximum possible overall score‡ | 12 | |||||
| Low risk: 0-2 score, moderate risk 3-6 score, high risk 7-12 score | ||||||
CI, confidence interval.
Adjusted for year of RSV diagnosis and ribavirin-based therapy at the URTI stage to identify the independent effect of each immunodeficiency indicator on progression to LRTI.
Within the prior 30 days.
The overall score equals the sum of the scores for the immunodeficiency indicators present at the time of diagnosis of RSV infection. For example, for a patient with an ANC <500/μL (ISI-RSV score 3) and acute GVHD (ISI-RSV score 1), the total ISI-RSV score would be 4, and the patient would be stratified into the moderate-risk group.